Wellborn Pharmaceuticals Private Limited
About Wellborn Pharmaceuticals Private Limited
Data last updated:
Wellborn Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 19 September 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2012PTC242504. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Shyam Kishor Sahay and Rakesh Kumar Sinha.
Its last annual general meeting (AGM) was held on 29 September 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office is at 430 A Sant Nagar East Of Kailash, New Delhi, Delhi, India – 110067.
As per the financials filed for FY 2018, the company reported a revenue of ₹8.44 Lakh, a decline of 43% compared to the previous year. For the same year it recorded a net loss of ₹14,358 (net margin -1.7%) and EBITDA of ₹52,409 (EBITDA margin 6.2%). Revenue has declined at a compounded annual rate (CAGR) of 7% over three years.
As per MCA filings, the company has open charges of ₹8 Lakh on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies.
Company details
Contact details
Wellborn Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address430 A Sant Nagar East Of Kailash, New Delhi, Delhi, India – 110067
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Wellborn Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Wellborn Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Wellborn Pharmaceuticals Private Limited, buy the company report.
Financials of Wellborn Pharmaceuticals Private Limited
FY 2018 filings availableWellborn Pharmaceuticals Private Limited reported revenue of ₹8.44 Lakh (down 43% YoY) for FY 2018.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 7% over three years, including a 43% fall in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹52,409 | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹14,358 | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 6.2% | |||
| Net Profit Margin | -1.7% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Wellborn Pharmaceuticals Private Limited, buy the company report.
Board of directors of Wellborn Pharmaceuticals Private Limited
Wellborn Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shyam Kishor Sahay | Director | 19 Sep 2012 | 14 Years 1 Months | Current |
| Rakesh Kumar Sinha | Director | 19 Sep 2012 | 14 Years 1 Months | Current |
Peer comparison
Wellborn Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Hyssop Pharmaceuticals Private Limited | ₹8.5 Lakh (FY 2024) | -55.0% | Ranchi, Jharkhand, India | |||
| Endospy Pharmaceuticals Private Limited | ₹8.48 Lakh (FY 2025) | 70.0% | Pune, Maharashtra, India | |||
| Trans Pharmaceuticals Private Limited | ₹8.48 Lakh (FY 2021) | -85.0% | Ahmednagar, Maharashtra, India | |||
| Wellborn Pharmaceuticals Private Limitedthis company | ₹8.44 Lakh (FY 2018) | -₹14,358 | -1.7% | -43.0% | New Delhi, Delhi, India | |
| Kon Pharmaceuticals Trading Private Limited | ₹8.43 Lakh (FY 2025) | 13.0% | Burdwan, West Bengal, India | |||
| Vagmin Pharmaceuticals Private Limited | ₹8.43 Lakh (FY 2019) | Bangalore, Karnataka, India |
To see the full peer comparison of Wellborn Pharmaceuticals Private Limited, buy the company report.
Auditor
Wellborn Pharmaceuticals Private Limited is audited by BNKedia& Company for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BNKedia& Company | FY 2017 | 001652N |
Shareholding
The shareholding of Wellborn Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Wellborn Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Jun 2014 | 10505340 | Others | ₹8 Lakh | Open |
To see the full charge records of Wellborn Pharmaceuticals Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Wellborn Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Wellborn Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Wellborn Pharmaceuticals has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Wellborn Pharmaceuticals Private Limited, buy the company report.
Recent activity
Wellborn Pharmaceuticals Private Limited has 2 board changes on record since 2012: 2 appointments. The latest: Rakesh Kumar Sinha was appointed as Director on 19 Sep 2012.
Frequently asked questions
Wellborn Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in wholesale, within the trading industry. It was incorporated on 19 September 2012 (14+ years old) and is registered under CIN U51909DL2012PTC242504.
Wellborn Pharmaceuticals has 2 current directors:
- Shyam Kishor Sahay - Director
- Rakesh Kumar Sinha - Director
The latest financial statements of Wellborn Pharmaceuticals on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 29 September 2018. Year-wise statements from 2015 are in the company report.
No. Wellborn Pharmaceuticals has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Wellborn Pharmaceuticals is U51909DL2012PTC242504. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Wellborn Pharmaceuticals was incorporated on 19 September 2012, making it 14+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Wellborn Pharmaceuticals by revenue are Hyssop Pharmaceuticals Private Limited, Endospy Pharmaceuticals Private Limited, Trans Pharmaceuticals Private Limited, Kon Pharmaceuticals Trading Private Limited, Vagmin Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Rakesh Kumar Sinha was appointed as Director on 19 Sep 2012. Shyam Kishor Sahay was appointed as Director on 19 Sep 2012.
The registered office of Wellborn Pharmaceuticals is at 430 A Sant Nagar East Of Kailash, New Delhi, Delhi, India – 110067.
Wellborn Pharmaceuticals operates in the trading industry, in the wholesale segment.
Wellborn Pharmaceuticals has open charges of ₹8 Lakh and no satisfied charges on record as per latest MCA filings.